Targeted inhibition of Rictor leads to growth inhibition and induces apoptosis in both rapamycin-sensitive and rapamycin-resistant CRCs, suggesting that selective targeting of mTORC2 may represent a novel therapeutic strategy for treatment of CRC (36). Here, RICTOR is linked to colorectal carcinoma.